Clinical trial

Sorafenib in Treating Patients With Metastatic or Recurrent Prostate Cancer

NCT00093457

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2004-08-10

PhasePHASE2

Study timeline

Study start (actual)2004-08-10Date precision: day

Registry last updated2023-08-04

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Prostate Cancerunresolved

Interventions

sorafenib tosylateDRUG · verified · RxNorm: sorafenib tosylate

Sponsors & collaborators

NCIC Clinical Trials Grouplead sponsor

National Cancer Institute (NCI)collaborator

Mapped research locations

TorontoOntario, Canada1 VancouverBritish Columbia, Canada1 LondonOntario, Canada1 CalgaryAlberta, Canada1 HamiltonOntario, Canada1 WinnipegManitoba, Canada1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00093457 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.